THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC

As filed

Subsection

03

NTEE code

G50

Classification

1000

Street

383 MAIN AVE STE 7

These codes are the IRS's own and are shown exactly as filed. What each one means is in the Business Master File documentation (opens in a new tab).

Mission and programs · 2025

• THE MULTIPLE MYELOMA RESEARCH CONSORTIUM (MMRC), THE CLINICAL RESEARCH SUBSIDIARY OF THE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF), IS A COLLABORATIVE NETWORK OF LEADING CANCER CENTERS DRIVING CUTTING-EDGE CLINICAL TRIALS. THE MMRF LAUNCHED THE HORIZON CLINICAL TRIALS PROGRAM THROUGH THE MMRC TO DRIVE PROGRESS FOR PATIENTS WHO NEED IT MOST. HORIZON TRIALS USE AN ADAPTIVE PLATFORM DESIGN THAT ALLOWS RESEARCHERS TO TEST SEVERAL TREATMENTS AT THE SAME TIME AND ADD NEW OPTIONS AS DATA BECOMES AVAILABLE. IN 2025, THE HORIZON ONE TRIAL FOCUSED ON RELAPSED/REFRACTORY MYELOMA EXCEEDED MANY OF ITS ENROLLMENT GOALS FOR ITS FIRST TREATMENT ARM, WHICH IS TESTING DOSING APPROACHES FOR A BISPECIFIC ANTIBODY. THE TRIAL SO FAR HAS ENROLLED MORE BLACK PATIENTS AND OLDER ADULTSTWO GROUPS THAT HAVE HISTORICALLY BEEN LEFT OUT OF RESEARCHTHAN MOST MYELOMA TRIALS. HORIZON ONE BECAME THE FIRST-EVER MYELOMA CLINICAL TRIAL IN FLINT, MICHIGAN, AND IT OPENED AT 25 COMMUNITY HOSPITALS AND CLINICS LAST YEAR. ALSO IN 2025, 13 SITES ENTERED THE START-UP PHASE IN THE HORIZON TWO CLINICAL TRIAL FOCUSED ON HIGH-RISK, NEWLY DIAGNOSED MYELOMA SO THEY COULD FULLY OPEN AND BEGIN SCREENING PATIENTS IN 2026.

  Expenses $6,096,220 · Revenue $8,674,361

• DATA HELPS DRIVE EVERY BREAKTHROUGH IN MYELOMA. BY BUILDING AND SHARING LARGE, HIGH-QUALITY DATASETS, THE MMRF IS CREATING A LAUNCHPAD FOR THE NEXT WAVE OF TREATMENTS, IMPROVEMENTS IN CARE, AND, ULTIMATELY, CURES. IN 2025, THE MMRF LAUNCHED ITS NEXT INNOVATION IN DATA SHARING: THE MMRF VIRTUAL LABTM. VIRTUAL LAB IS NOW MYELOMA'S LARGEST, MOST-COMPREHENSIVE DATA-SHARING PLATFORM AND BRINGS ALL THE MMRF'S DATA INTO ONE PLACE. THE PLATFORM AND ITS ROBUST DATA WILL EMPOWER RESEARCHERS TO ASK BIGGER QUESTIONS, TEST NEW HYPOTHESES, AND ACCELERATE DISCOVERIES THAT IMPROVE OUTCOMES FOR PATIENTS WITH MYELOMA.

  Expenses $2,669,588

• THE MAC PROGRAM PROVIDES $21 MILLION OVER 3 YEARS TO CREATE MULTICENTER TRANSLATIONAL RESEARCH TEAMS ACROSS GLOBAL MEDICAL CENTERS. EACH OF THESE THREE-YEAR MULTICENTER TRANSLATIONAL PROJECTS AIM TO FOSTER COLLABORATION AND ADVANCE COMPELLING HYPOTHESES THAT ARE READY FOR RAPID TESTING IN CLINICAL TRIALS, A CRITICAL STEP IN THE MMRF'S URGENT PURSUIT OF A CURE FOR EACH AND EVERY MYELOMA PATIENT. THE GRANTS ARE FOCUSED ON TWO CRITICAL AREAS OF UNMET NEED: OPTIMIZING FIRST-LINE THERAPY FOR NEWLY DIAGNOSED HIGH-RISK MYELOMA AND IMPROVING IDENTIFICATION OF HIGH-RISK SMOLDERING MYELOMA (HR SMM), AN EARLY, ASYMPTOMATIC STAGE THAT CAN PROCEED TO ACTIVE MYELOMA. IN 2025 THE COLLABORATING CENTERS CONTINUED TO MAKE POSITIVE PROGRESS, SHOWING THAT POOLING RESOURCES AND SAMPLES ACROSS A NETWORK OF INSTITUTIONS DRAMATICALLY IMPROVES THE ABILITY TO DRIVE MEANINGFUL RESULTS.

  Expenses $1,600,000

• BEYOND THE PROGRAM EXPENSES OUTLINED ABOVE, THE MMRF ALSO SUPPORTS A RANGE OF STRATEGIC INITIATIVES ALIGNED WITH ITS BROADER MISSION. THIS INCLUDES A ROBUST PORTFOLIO OF CUTTING-EDGE BASIC SCIENCE AND TRANSLATIONAL RESEARCH AIMED AT IDENTIFYING NEW THERAPEUTIC TARGETS THROUGH GENOMICS AND PROTEOMICS; VALIDATION STUDIES TO EXPLORE PROMISING COMPOUNDS AND TREATMENT COMBINATIONS; AND INNOVATIVE CLINICAL TRIALS FOCUSED ON NOVEL AND COMBINATION THERAPIES.FOUNDED BY PATIENTS, THE MMRF IS DEEPLY COMMITTED TO THOSE IMPACTED BY MYELOMA: PATIENTS, FAMILIES, PHYSICIANS, RESEARCHERS, AND INVESTORS. AT THE SAME TIME, THE MMRF DISTINGUISHES ITSELF THROUGH ITS BOLD AND COLLABORATIVE APPROACH. WE GENERATE, ANALYZE, AND SHARE THE LARGEST, MOST COMPREHENSIVE SET OF HIGH-QUALITY MYELOMA DATA, MAKING IT PUBLICLY AVAILABLE TO ACCELERATE PROGRESS. BY BRINGING TOGETHER THE RIGHT PEOPLE, PROGRAMS, AND TECHNOLOGIES, THE MMRF IS DRIVING THE RAPID DISCOVERY OF CURES FOR EACH AND EVERY PATIENT.

  Expenses $16,987,283 · Grants $3,576,906 · Revenue $70,864

As filed on the 2025 return. The filer continues this part on Schedule O, which is not shown here.

Officers and directors · 2025

As listed in Part VII of the 2025 return, in the order the filer printed them. Each return names its own; this is not a roster the organization keeps with us.

The first 25 listed. Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us. Earlier years are each on their own filing page.

Filings

• 2025

  Revenue

  $36,523,356

  Expenses

  $34,651,131

  Contributions

  $26,628,081

  Grants paid

  $3,576,906

• 2024

  Revenue

  $29,101,414

  Expenses

  $35,604,337

  Contributions

  $24,100,727

  Grants paid

  $6,080,876

• 2023

  Revenue

  $33,950,590

  Expenses

  $41,890,829

  Contributions

  $30,976,388

  Grants paid

  $8,051,387

• 2022

  Revenue

  $45,044,474

  Expenses

  $38,280,730

  Contributions

  $42,022,114

  Grants paid

  $4,589,741

The four totals the IRS asks for on Part I of the Form 990, as filed. A dash means the figure was not present on the return — not that it was zero.

Other returns filed

• 2021 · 990

  Revenue

  $42,311,196

  Expenses

  $37,647,063

  Assets (EOY)

  $85,401,847

• 2020 · 990

  Revenue

  $26,787,219

  Expenses

  $28,545,732

  Assets (EOY)

  $73,276,923

• 2019 · 990

  Revenue

  $43,968,062

  Expenses

  $33,588,092

  Assets (EOY)

  $79,154,355

• 2018 · 990

  Revenue

  $44,172,260

  Expenses

  $36,242,359

  Assets (EOY)

  $69,711,900

• 2017 · 990

  Revenue

  $45,691,025

  Expenses

  $30,536,598

  Assets (EOY)

  $56,487,907

• 2016 · 990

  Revenue

  $36,113,277

  Expenses

  $27,260,474

  Assets (EOY)

  $37,562,966

• 2015 · 990

  Revenue

  $28,896,409

  Expenses

  $29,637,872

  Assets (EOY)

  $22,963,398

• 2014 · 990

  Revenue

  $28,639,741

  Expenses

  $25,926,480

  Assets (EOY)

  $24,223,758

• 2013 · 990

  Revenue

  $23,227,427

  Expenses

  $23,166,776

  Assets (EOY)

  $22,436,221

• 2013 · 990

  Revenue

  $23,227,427

  Expenses

  $23,166,776

  Assets (EOY)

  $22,436,221

Nonprofiteer parses Forms 990, 990-EZ and 990-PF, in a window of recent tax years. These returns are recorded from the IRS e-file index, so their figures were extracted by that index rather than read from the return here — treat them as a different source from the filings above, not as more of the same record. A dash means the index carries no figure; Form 990-T listings carry none at all. Showing the 10 most recent; the API carries the rest.

Form 990-N e-Postcard, tax year 2013

Tax period

1 January 2013 to 31 December 2013

Principal officer

Jessica Parnell

Mailing address

1105 WilsonRichland WA 99354

Website

www.parnellgolfclassic.com

As filed, from the IRS e-Postcard file of 26 October 2026. The IRS publishes only each organization's most recent postcard, so earlier years are not shown. A 990-N carries no financial detail. The postcard also gives the principal officer's address, which is not shown here.

Grants made

• DANA FARBER CANCER INSTITUTE

  $2,804,526

  2022 · SITE INVESTMENT GRANT, IMMUNOTHERAPY, PREVENTION

• ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

  $1,964,644

  2023 · SITE INVESTMENT GRANT, IMMUNOTHERAPY

• ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

  $1,900,000

  2024 · SITE INVESTMENT GRANT, IMMUNOTHERAPY, MYELOMA ACCELERATOR CHALLENGE GRANT

• ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

  $1,150,000

  2025 · SITE INVESTMENT GRANT, MAC GRANT

• DANA FARBER CANCER INSTITUTE

  $1,050,000

  2023 · SITE INVESTMENT GRANT, IMMUNOTHERAPY, PREVENTION

• DANA FARBER CANCER INSTITUTE

  $1,000,000

  2024 · SITE INVESTMENT GRANT, PREVENTION

• BETH ISRAEL DEACONESS MEDICAL CENTER

  $860,550

  2024 · SITE INVESTMENT GRANT, IMMUNOTHERAPY

• WASHINGTON UNIVERSITY IN ST LOUIS

  $806,802

  2023 · SITE INVESTMENT GRANT, IMMUNOTHERAPY

• BETH ISRAEL DEACONESS MEDICAL CENTER

  $632,000

  2022 · SITE INVESTMENT GRANT, IMMUNOTHERAPY

• EMORY UNIVERSITY

  $613,060

  2023 · SITE INVESTMENT GRANT, FELLOW, IMMUNOTHERAPY, PREVENTION

The 10 largest by cash amount. The API serves every itemized grant.

Where these grants went next →

Grants received

• VANGUARD CHARITABLE ENDOWMENT PROGRAM

  $2,218,343

  2022 · FOR RECIPIENT'S EXEMPT PURPOSE

• FIDELITY INVESTMENTS CHARITABLE GIFT FUND

  $1,130,779

  2024 · For grant recipient's exempt purposes

• FIDELITY INVESTMENTS CHARITABLE GIFT FUND

  $1,013,249

  2022 · For grant recipient's exempt purposes

• FIDELITY INVESTMENTS CHARITABLE GIFT FUND

  $787,326

  2023 · For grant recipient's exempt purposes

• DONOR ADVISED CHARITABLE GIVING

  $373,262

  2023 · HEALTH

• AMERICAN ONLINE GIVING FOUNDATION INC

  $351,594

  2024 · GENERAL SUPPORT

• DONOR ADVISED CHARITABLE GIVING

  $322,743

  2024 · HEALTH

• AMERICAN ONLINE GIVING FOUNDATION INC

  $298,422

  2023 · GENERAL SUPPORT

• PAYPAL CHARITABLE GIVING FUND

  $275,423

  2024 · GENERAL SUPPORT

• AMERICAN ONLINE GIVING FOUNDATION INC

  $263,954

  2022 · GENERAL SUPPORT

The 10 largest by cash amount. The API serves every itemized grant.

Taxable family

From Schedule R Parts I, III and IV: entities that legally are the filer, and taxable partnerships, corporations and trusts it is related to. These record ownership and control, not shared board members or money.

Other IRS files